Hyperaldosteronism Clinical Trial
Official title:
Phase 2 Study Evaluating the Functional Status of the Adrenal Glands With [68Ga]Ga-PentixaFor in Hyperaldosteronism and Hypercortisolism
Background: The adrenal glands are 2 small organs that sit on top of each kidney. They release hormones; these are chemicals that control how the body works. Tumors on or outside the adrenal glands are called functional if they release hormones; they are called nonfunctional if they do not. Doctors who treat adrenal tumors need to know which type a person has. Researchers want to find better ways to learn whether an adrenal tumor is functional. Objective: To see if a new radioactive tracer ([68Ga]Ga-PentixaFor) can make it easier to identify functional adrenal tumors with positron emission tomography (PET) scans. Eligibility: People aged 18 years and older with 1 or more adrenal tumors. They must have increased levels of the hormones aldosterone or cortisol. They must also be enrolled in at least 1 other related NIH study (protocols 19-DK-0066, 18-CH-0031, or 09-C-0242). Design: Participants will be screened. They may have imaging scans. Their ability to perform normal activities will be reviewed. Participants will have one PET scan with the study tracer. The tracer will be given through a tube attached to a needle inserted into a vein. Participants will receive the tracer 1 hour before the scan. They will lie still on a bed while a machine captures images of the inside of their body. The scan will take 45 to 90 minutes. Participants heart rate, blood pressure, and rate of breathing will be checked before, during, and after the scan. Participants will have a follow-up visit 3 days after their scan. This visit can be by phone, email, or in person.
Background: - [68Ga]Ga-PentixaFor is a PET agent targeting the C-X-C chemokine receptor type 4 (CXCR4) with promising applications in oncology, cardiology, and infectious disease. - CXCR4 has also been noted to show high expression in many aldosterone-producing adenomas (APA) and some cortisol-producing adenomas (CPA) but not usually in nonfunctioning adenomas. - [68Ga]Ga-PentixaFor may be useful in the evaluation of adrenal adenomas in the setting of Conn s or Cushing s syndrome. Localizing functional adenomas is important for managing treatment options but current imaging modalities are either too invasive or insufficiently able to differentiate adrenal conditions. Objective: -To estimate the percent concordance of [68Ga]Ga-PentixaFor imaging with clinical diagnosis in identifying functional adrenal or extra-adrenal adenomas in hyperaldosteronism and hypercortisolism Eligibility: - Must have either of the following: - one or more adrenal masses on CT and/or MRI with biochemical evidence of excess aldosterone or ACTH-independent hypercortisolism, OR - history of ACTH-dependent hypercortisolism (with or without adrenal enlargement). - Age >= 18 years - ECOG performance status <= 2 Design: - This is a Phase II, single site study where participants from three cohorts are enrolled into one arm according to their probable disease: primary aldosteronism (Cohort 1), ACTHindependent Cushing s syndrome (Cohort 2), or ACTH-dependent Cushing s syndrome (Cohort 3). - All participants will undergo a [68Ga]Ga-PentixaFor PET/CT or [68Ga]Ga-PentixaFor PET/MR. - A safety visit will be performed 3 days following the [68Ga]Ga-PentixaFor imaging. - Participants will remain on-study for 1 year until samples are obtained for correlative analysis from the parent protocol (adrenal venous sampling, imaging assessments, laboratory evaluations, and/or tissue samples). - To account for inevaluable participants, the accrual ceiling will be set to 77 maximum participants with the number of evaluable participants enrolled as follows: 20 for Cohort 1, 20 for Cohort 2, and 30 for Cohort 3. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06008184 -
Real-time Monitoring of Cortisol - Comparison of Cortisol Levels in Four Biological Fluids
|
||
Recruiting |
NCT02945904 -
IS Metomidate PET-CT Superior to Adrenal Venous Sampling in Predicting Outcome From Adrenalectomy in Patients With Primary Hyperaldosteronism
|
||
Completed |
NCT01431326 -
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
|
||
Not yet recruiting |
NCT00553722 -
Does Aldosterone Cause Hypertension by a Non-Renal Mechanism?
|
Phase 4 | |
Completed |
NCT01234220 -
Adrenal Vein Sampling International Study (AVIS Study)
|
N/A | |
Completed |
NCT00001176 -
Effects of Salt Intake on the Nervous Systems of Patients With Salt-Sensitive High Blood Pressure
|
N/A | |
Active, not recruiting |
NCT04605549 -
A Study of CIN-107 in Adults With Primary Aldosteronism
|
Phase 2 | |
Not yet recruiting |
NCT03414918 -
Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA)
|
N/A | |
Completed |
NCT02751021 -
Sleep Apnea Diagnosis Using a Novel Pacemaker Algorithm and Link With Aldosterone Plasma Level in Patients Presenting With Diastolic Dysfunction
|
N/A | |
Recruiting |
NCT02832388 -
Primary Aldosteronism in Western Norway
|
||
Completed |
NCT00004354 -
Study of Prevalence and Clinical Phenotype in Patients With Glucocorticoid-Remediable Aldosteronism
|
N/A | |
Completed |
NCT01096654 -
SPARTACUS: Subtyping Primary Aldosteronism: a Randomized Trial Comparing Adrenal Vein Sampling and Computed Tomography Scan.
|
Phase 3 | |
Completed |
NCT00155064 -
Kallikrein-kinin (KKS) and Renin-angiotensin-aldosterone System (RAAS) in Primary Aldosteronism
|
Phase 4 | |
Recruiting |
NCT03778645 -
Adrenal Venous Sampling Via an Antecubital Approach
|
||
Recruiting |
NCT04328181 -
Comparison of Imaging Quality Between Spectral Photon Counting Computed Tomography (SPCCT) and Dual Energy Computed Tomography (DECT)
|
N/A | |
Active, not recruiting |
NCT02030587 -
Laparoscopic Adrenalectomy Versus Radiofrequency Ablation
|
N/A | |
Completed |
NCT01897727 -
Etiology of Sleep Apnea-related Hyperaldosteronism - BP Treatment
|
N/A | |
Recruiting |
NCT00407784 -
Diagnostic Properties of Aldosterone-Renin Ratio in Primary Aldosteronism Among Hypertensives.
|
N/A | |
Recruiting |
NCT00451672 -
The Therapeutic Effect of Bromocriptin in Patients With Primary Aldosteronism
|
Phase 4 | |
Not yet recruiting |
NCT06192238 -
China National Study of Adrenal Venous Sampling
|